For the quarter ending 2026-03-31, COR had $427,569K increase in cash & cash equivalents over the period. $1,173,021K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 1,629,528 | 566,126 | -333,071 | 689,749 |
| Depreciation, including amounts charged to cost of goods sold | 142,302 | 135,247 | 133,728 | 130,356 |
| Amortization, including amounts charged to interest expense | 120,675 | 129,024 | 130,270 | 128,617 |
| (benefit) provision for credit losses | -4,885 | 13 | 17,792 | 33,159 |
| Provision for deferred income taxes | 178,407 | 14,362 | 55,389 | -16,658 |
| Share-based compensation expense | 28,002 | 66,054 | 25,943 | 23,184 |
| Lifo (credit) expense | -210,030 | -77,562 | -56,962 | -52,058 |
| Trkiye highly inflationary impact | 10,474 | 8,723 | 12,660 | 16,799 |
| Impairment of assets, including goodwill | 0 | 249,498 | 837,378 | - |
| Adjustments to rca and oneoncology equity units | 92,905 | -32,783 | - | 37,460 |
| Adjustments-Contingent Consideration Equity Units | - | - | 121,666 | - |
| Remeasurement gain related to oneoncology acquisition (note 2) | 1,086,612 | - | - | - |
| Adjustments-Contingent Consideration Predefined Business Objective | - | - | 19,550 | - |
| Loss on divestiture of businesses | 0 | 0 | 0 | 0 |
| Gain on remeasurement of equity investment | 0 | 10,501 | -16,501 | 27,259 |
| Gain on divestiture of equity investment | - | - | 0 | 12,838 |
| Gain on sale of assets | 234 | 35,816 | - | - |
| Other, net | 5,681 | -6,726 | 3,594 | 39,768 |
| Accounts receivable | -522,077 | 830,752 | 945,803 | 759,565 |
| Inventories | -3,399,637 | 3,519,839 | 319,548 | 984,133 |
| Prepaid expenses and other assets | -68,490 | 14,386 | 63,957 | -143,541 |
| Accounts payable | -3,501,753 | 1,307,868 | 3,755,256 | 607,587 |
| Accrued expenses | 70,971 | -328,365 | 295,519 | -316,650 |
| Income taxes payable and other liabilities | -78,174 | -13,726 | -86,278 | 18,254 |
| Long-term accrued litigation liability | - | - | -404,102 | 0 |
| Net cash (used in) provided by operating activities | 1,338,639 | -2,305,169 | 3,133,417 | 109,247 |
| Capital expenditures | 165,618 | 119,376 | 249,812 | 183,216 |
| Cost of acquired companies, net of cash acquired | 4,712,350 | 219,686 | 91,410 | 56,459 |
| Proceeds from sale of assets | 717 | 43,057 | - | - |
| Cost of equity investments | 8,500 | 10,710 | 2,450 | 1,216 |
| Non-customer note receivable | 20,626 | 0 | 0 | 34,814 |
| Other, net | 9,776 | -7,400 | -21,732 | -6,200 |
| Net cash used in investing activities | -4,874,901 | -299,315 | -321,940 | -234,691 |
| Senior notes and loan borrowings | 4,540,483 | 107,720 | 0 | 4,508,482 |
| Senior notes and loan repayments | 217,784 | 131,709 | 517,203 | 756,143 |
| Borrowings under revolving and securitization credit facilities | 47,212,956 | 23,791,590 | 45,980,788 | 42,521,709 |
| Repayments under revolving and securitization credit facilities | 47,424,106 | 23,501,389 | 46,045,822 | 43,172,266 |
| Purchases of common stock | 0 | 0 | 0 | 0 |
| Exercises of stock options | - | 7,598 | 6,520 | 6,835 |
| Cash dividends on common stock | 117,456 | 126,516 | 107,512 | 107,493 |
| Employee tax withholdings related to restricted share vesting | 7,035 | 98,151 | 109 | 116 |
| Other, net | -893 | -5,939 | -444 | -6,146 |
| Net cash provided by financing activities | 3,978,567 | 43,204 | -683,782 | 215,484 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 9,751 | -24,576 | -8,472 | 6,720 |
| Decrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for sale | -2,133,800 | - | - | - |
| Less increase in cash classified within assets held for sale | -24,487 | - | - | - |
| Decrease in cash, cash equivalents, and restricted cash | 427,569 | -2,585,856 | 2,119,223 | 96,760 |
| Cash, cash equivalents, and restricted cash at beginning of period | 1,808,693 | 4,394,549 | 2,275,326 | 2,178,566 |
| Cash, cash equivalents, and restricted cash at end of period | 2,236,262 | 1,808,693 | 4,394,549 | 2,275,326 |
Cencora, Inc. (COR)
Cencora, Inc. (COR)